DOCSLIB.ORG

Pharmacological Analysis of Positive Chrono and Inotropic Responses To

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pharmacological Analysis of Positive Chrono and Inotropic Responses To Pharmacological Analysis of Positive Chrono and Inotropic Responses to Denopamine (TA-064) in Dog Cross-Circulated Atrial and Ventricular Preparations KunioAKAHANE, Yasuyuki FURUKAWA, Yasuyuki KARASAWA, Lei-MingREN and ShigetoshiCHIBA* Departmentof Pharmacology,Shinshu University School of Medicine, Matsumoto390, Japan AcceptedSeptember 21, 1989 Abstract-Positive chrono and inotropic responses to denopamine (TA-064, (-) (R)-1-(p-hydroxyphenyl)-2-[(3,4-dimethoxyphenethyl)amino] ethanol), a new and orally active cardiotonic agent, were investigated in the canine isolated right atrial or left ventricular preparation which was cross-circulated with blood from another support dog. Denopamine dose-dependently increased the sinus rate, right atrial and left ventricular contractile force. Denopamine was one to two orders of mag nitude less potent than isoproterenol. The positive chrono and inotropic effects of denopamine in isolated, blood-perfused right atria were dose-dependently in hibited by treatment with propranolol and atenolol. The effects of denopamine were only slightly attenuated by ICI 118,551 in doses which completely suppressed the positive chrono and inotropic effects of procaterol. The increases in sinus rate and atrial contractility induced by denopamine were partially but significantly attenuated by treatment with imipramine in a dose which suppressed the effects of tyramine and potentiated the effects of norepinephrine. These results indicate that denopamine is a highly selective beta-1 adrenoceptor agonist in isolated, blood perfused dog heart preparations, and they also suggest a mild catecholamine releasing activity through tyramine-like action in isolated right atria. Congestive heart failure is characterized by Recently, orally active positive Inotropic com a state of insufficient cardiac output to fulfill pounds have been developed which have the metabolic requirements of the body. One beta -sympathom1metic (1-4) or phosphodies of the therapies for congestive heart failure is terase inhibiting action (5-9), and these agents augmenting the cardiac pumping function are structurally unrelated to cardiac gly (positive Inotropic action). Cardiac gly cosides. Denopamine, a newly synthesized cosides are the drugs used for producing phenylethanolamine derivative, is the former Positive inotropic effects, but their effec type of cardiotonic agent. Ikeo et al. (10) have tiveness and safety remain controversial be reported that, administered parenterally or cause of their toxicity. Some catecholamines orally, denopamine induced a significant such as dopamine and dobutamine, which dose-dependent increase in contractile force have a strong positive inotropic effect, are and dp/dtmax in the left ventricle with a little clinically available only by intravenous ad change in heart rate in anesthetized and con ministrations. Therefore, potent positive Ino scious dogs. The cardiotonic effects of tropic drugs which are orally active and pos denopamine with a weak arrhythmogenic ac sess a wide margin of safety are of great tivity were also demonstrated in guinea pigs, interest in the treatment of heart failure. rabbits, cats, monkeys, rats and pigs (11-14). Kino et al. (15) have revealed that the in To whom correspondence should be addressed. travenous infusion of denopamine produced a marked increase in dp/dtmax in the left ventri pump (Harvard Apparatus model 1210). A cle without significant effects on heart rate in pneumatic resistance was placed in parallel both normal and diseased human hearts. The with the perfusion system so that the per mechanism of the cardiotonic activity of fusion pressure could be maintained at 100 denopamine mainly involves its ability to mmHg. The blood flow rate to the isolated selectively stimulate cardiac beta-1 receptors atrium was 6 to 11 ml/min. The venous ef (16-18). However, many of the studies were fluent from the preparation was led to a col performed by in vivo experiments or by the lecting funnel, from which it was returned Langendorff's method using small animals continuously to the support dog via the ex such as guinea pigs or rabbits in which beta ternal jugular vein. The ventricular margin of 2 adrenoceptors have a minor role for in the atrium was attached to a rigid stainless creasing heart rate or cardiac contractility steel bar, and the preparation was placed in a (19-22). Recently, we have reported the glass container which was kept at a constant existence of positive chrono and inotropic temperature of 37'C by means of a heating responses mediated by beta-2 adrenoceptors bath circulator (Haake FE 2). The upper part in addition to predominant beta-1 adreno of the atrium was connected to a force-dis ceptors in isolated, blood-perfused right atrial placement transducer (Nihon Kohden AP and left ventricular preparations of the dog 620 G) by a silk thread. The atrial muscle was (23). Therefore, this study was designed to usually stretched to a resting tension of 2 g. examine the direct cardiac effects of denop The isometric tension was recorded on a amine on isolated, b!ood-perfused right atrial thermo-writing rectigraph (Nihon Kohden and left ventricular preparations of the dog WT 685T). A pair of silver electrodes was which are free from extracardiac modifica brought into contact with the epicardial tions such as autonomic nervous reflexes. surface of the isolated atrium to record the atrial electrogram. The tachometer was driven Materials and Methods by the atrial electrogram. Preparation of the isolated, blood-perfused The left ventricular muscle along the right atrial or left ventricular muscle: Experi anterior descending branch of the left coro ments were carried out on mongrel dogs of nary artery was excised, and the anterior either sex anesthetized with sodium pento descending artery was cannulated. The left barbital (30 mg/kg, i.v.). Isolated right atria or ventricular preparation was perfused with the left ventricles were obtained from 28 recipient heparinized blood from the support dog using dogs weighing 7 to 16 kg, and each prepara the same perfusion system for the right atrial tion was perfused with arterial blood from a preparation. A pair of bipolar silver electrodes second support dog. The details of these prep was sewn on the ventricular free wall, and the arations have been described in Previous preparation was driven by an electrical stimu papers (24-26). Sodium heparin (500 USP lator (Nihon Kohden SEN 7103) at a fre units/kg, i.v.) was administered to each dog quency of 2 Hz with square wave pulses of 2 at the beginning of the perfusion, and 200 msec duration and twice the threshold voltage USP units/kg were given each hour thereafter. (usually 4 V). The left ventricular tension After heparin (200 USP units/kg, i.v.) was development was measured isometrically by a administered, the right atrium or the left force-displacement transducer through a fine ventricle was excised and immersed in cold thread connected to a ventricular surface. The Ringer's solution. The wet weight of the resting tension of the ventricular muscle was isolated right atrial and left ventricular prep 2 g. arations varied from 8 to 16 g and 10 to 18 g, The femoral arterial blood pressure and respectively. heart rate derived from the ECG lead II of the In the right atrial preparation, the sinus support dog and the blood flow rate to a prep node artery was cannulated via the right aration were simultaneously recorded. coronary artery, and it was perfused with Drugs: The drugs used in the experiments heparinized blood led from the carotid artery were denopamine (TA-064, (-)-(R)-1-(p of the support dog with the aid of a peristaltic hydroxyphenyl) -2 [(3,4-dimethoxypheneth yl) amino]ethanol, generously donated by usually assessed 1-1.5 min after treatment Tanabe Seiyaku Co., Ltd., Osaka, Japan), / with an antagonist. isoproterenol hydrochloride (Nikken Kagaku), Statistical analysis: All changes in positive d,/-norepinephrine hydrochloride (NE, San chrono and inotropic responses induced by kyo), procaterol hydrochloride (Otsuka), each dose of substance were expressed as tyramine hydrochloride (Wako Pure Chemi percent changes from their predrug levels. cal), propranolol hydrochloride (Sigma), Values presented are means±S.E.M. Data, atenolol (Sigma), ICI 118,551 (generously which were obtained as the maximum re donated by Imperial Chemical Industries, sponses to each drug, were analyzed by Macclesfield, England) and imipramine Student's t-test for paired data. A P value less hydrochloride (Fujisawa). All drugs were than 0.05 was considered as statistically dissolved in physiological saline before the significant. start of the experiment. The volume of the Results drug solution injected into the sinus node artery of the isolated right atrium or the an Effects of denopamine, isoproterenol, NE terior descending branch of the isolated left and procaterol on sinus rate and tension ventricle was 0.01-0.03 ml over a period of 4 development in isolated right atria: When sec. The dose of a cardiotonic agent which denopamine was injected into the sinus node evoked about 50-60% increase in atrial con artery of the spontaneously beating dog right tracti!e force with an obvious chronotropic atrium, the drug dose-dependently increased response was roughly selected for the control the sinus rate and atrial contractile force, and response, i.e., denopamine at 1 or 3 nmol, EN the positive chrono and inotropic responses at 0.1 or 0.1 nmol, procaterol at 1 or 3 nmol to denopamine at high doses lasted more than and tyramine at 10 or 30 nmol, respectively. 10 min (Fig. 1). Dose-response curves of Since the effect of each antagonist appeared denopamine, isoproterenol, NE and pro in less than 1 min and continued for approxi caterol for the sinus rate and atrial tension mately 20-30 min, the positive chrono and development are shown in Fig. 2. The thresh inotropic responses to each agonist were old doses for increasing the sinus rate and Fig. 1. Typical tracings of positive chrono and inotropic responses to 0.3.
Load more

Recommended publications
  • Functional Evidence for Atypical Β-Adrenoceptors in Rat Isolated
    FUNCTIONAL EVIDENCE FOR ATYPICAL p-ADRENOCEPTORS IN RAT ISOLATED ARTERIES A thesis submitted by SONIA SOOCH for the degree of Doctor of Philosophy in the University of London. 1996 Department of Pharmacology University College London Gower Street London WCIE 6 BT ProQuest Number: 10055412 All rights reserved INFORMATION TO ALL USERS The quality of this reproduction is dependent upon the quality of the copy submitted. In the unlikely event that the author did not send a complete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion. uest. ProQuest 10055412 Published by ProQuest LLC(2016). Copyright of the Dissertation is held by the Author. All rights reserved. This work is protected against unauthorized copying under Title 17, United States Code. Microform Edition © ProQuest LLC. ProQuest LLC 789 East Eisenhower Parkway P.O. Box 1346 Ann Arbor, Ml 48106-1346 Abstract Since the original classification by Lands et al (1967a), it has become evident that not all (3-adrenoceptor mediated responses can be classified as either (3i or P 2, with the existence of an additional p-adrenoceptor subtype, referred to as the atypical or p 3-adrenoceptor. This p-adrenoceptor subtype has been identified in adipose and gastrointestinal tissue, as well as skeletal muscle and airway smooth muscle. The work presented in this thesis demonstrates the presence of atypical p-adrenoceptors in rat vasculature. The present in vitro results show that relaxations to isoprenaline in the rat thoracic aorta, mesenteric and pulmonary artery, are antagonized by propranolol in a non-competitive manner.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • Known Active Compounds Used in This Article
    Known active compounds used in this article As COX-2 active compounds, 12 inhibitors and 2 natural ligands were selected. The two natural ligands were arachidonic acid and prostaglandin H2. The 12 inhibitors were diclofenac, etodolac, suprofen, diflunisal, piroxicam, sulindac, indomethacin, ketoprofen, naproxen, nimesulide, rofecoxib, and 1-phenylsulfonamide-3-trifluoromethyl-5-parabromophenylpyrazole. The names of the thermolysin inhibitors used in the present study are as follows, with the PDB code in parentheses representing the complex structure from which the compound originated: l-benzylsuccinate (1hyt), phenylalanine phosphinic acid - deamino-methyl-phenylalanine (1os0), (6-methyl-3,4-dihydro-2H-chromen-2-Yl) methylphosphonate (1pe5), 2-(4-methylphenoxy) ethylphosphonate - 3-methylbutan-1-amine (1pe7), 2-ethoxyethylphosphonate - 3-methylbutan-1-amine (1pe8), (2-sulfanyl-3-phenylpropanoyl)-Phe-Tyr (1qf0), [2(R,S)-2-sulfanylheptanoyl]-Phe-Ala (1qf1), [(2S)-2-sulfanyl-3-phenylpropanoyl]-Gly-(5-phenylproline) (1qf2), n-(1-(2(R, S)-carboxy-4-phenylbutyl) cyclopentylcarbonyl)- (S)-tryptophan (1thl), (R)-retrothiorphan (1z9g), (S)-thiorphan (1zdp), hydroxamic acid (4tln), phenylalanine phosphinic acid (4tmn), Honh-benzylmalonyl-L-alanylglycine-P-nitroanilide (5tln), 1 Cbz-GlyP-Leu-Leu (ZgPLl) (5tmn), Cbz-GlyP-(O)-Leu-Leu (ZgP(O)Ll) (6tmn), CH2CO(N-OH)Leu-OCH3 (7tln), benzyloxycarbonyl-D-Ala (1kto), benzyloxycarbonyl-L-Ala (1kl6), benzyloxycarbonyl-D-Thr (1kro), benzyloxycarbonyl-L-Thr (1kj0), benzyloxycarbonyl-D-Asp (1ks7), benzyloxycarbonyl-L-Asp
    [Show full text]
  • ￎﾲ-Adrenergic Enhancement of Brain Kynurenic Acid Production Mediated
    Progress in Neuro-Psychopharmacology & Biological Psychiatry 33 (2009) 519–529 Contents lists available at ScienceDirect Progress in Neuro-Psychopharmacology & Biological Psychiatry journal homepage: www.elsevier.com/locate/pnpbp β-adrenergic enhancement of brain kynurenic acid production mediated via cAMP-related protein kinase A signaling Elzbieta Luchowska a, Renata Kloc a, Bartosz Olajossy a, Sebastian Wnuk a, Marian Wielosz a, Bjorn Owe-Larsson b, Ewa M. Urbanska a,c,⁎ a Department of Experimental and Clinical Pharmacology, Skubiszewski Medical University, Jaczewskiego 8, 20-090 Lublin, Poland b Department of Psychiatry, Karolinska University Huddinge Hospital, SE-141 86 Stockholm, Sweden c Department of Toxicology, Institute of Agricultural Medicine, Jaczewskiego 2, 20-950 Lublin, Poland article info abstract Article history: The central levels of endogenous tryptophan metabolite kynurenic acid (KYNA), an antagonist of N-methyl- Received 7 January 2009 D-aspartate (NMDA) and α7-nicotinic receptors, affect glutamatergic and dopaminergic neurotransmission. Received in revised form 29 January 2009 Here, we demonstrate that selective agonists of β1-receptors (xamoterol and denopamine), β2-receptors Accepted 1 February 2009 (formoterol and albuterol), α- and β-receptors (epinephrine), 8pCPT-cAMP and 8-Br-cAMP (analogues of Available online 12 February 2009 cAMP) increase the production of KYNA in rat brain cortical slices and in mixed glial cultures. Neither β β fl Keywords: betaxolol, 1-adrenergic antagonist, nor timolol, a non-selective 1,2-adrenergic antagonist has in uenced Glial culture synthesis of KYNA in both paradigms. In contrast, KT5720, a selective inhibitor of protein kinase A (PKA), Kynurenic acid strongly reduced KYNA formation in cortical slices (2–10 µM) and in glial cultures (100 nM).
    [Show full text]
  • Chromatographic Analysis of Pharmaceuticals Second Edition, Revised and Expanded
    Chromatographic Analysis of Pharmaceuticals Second Edition, Revised and Expanded edited by John A. Adamovics Cytogen Corporation Princeton, New Jersey Marcel Dekker, Inc. New York-Basel «Hong Kong Preface ISBN: 0-8247-9776-0 The first edition of Chromatographic Analysis of Pharmaceuticals was The publisher offers discounts on this book when ordered in bulk quanti­ published in 1990. The past years have allowed me to evaluate leads that I ties. For more information, write to Special Sales/Professional Marketing uncovered during the researching of the first edition, such as the first pub­ at the address below. lished example of the application of chromatography to pharmaceutical analysis of medicinal plants. This and other examples are found in a rela­ This book is printed on acid-free paper. tively rare book, Uber Kapillaranalyse und ihre Anwendung in Pharmazeu- tichen Laboratorium (Leipzig, 1992), by H. Platz. Capillary analysis, the Copyright © 1997 by Marcel Dekker, Inc. All Rights Reserved. chromatographic technique used, was developed by Friedlieb Runge in the mid-1850s and was later refined by Friedrich Goppelsroeder. The principle Neither this book nor any part may be reproduced or transmitted in any of the analysis was that substances were absorbed on filter paper directly form or by any means, electronic or mechanical, including photocopying, from the solutions in which they were dissolved; they then migrated to microfilming, and recording, or by any information storage and retrieval different points on the filter paper. Capillary analysis differed from paper system, without permission in writing from the publisher. chromatography in that no developing solvent was used. We find that, from these humble beginnings 150 years ago, the direct descendant of this Marcel Dekker, Inc.
    [Show full text]
  • G Protein‐Coupled Receptors
    S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2019/20: G protein-coupled receptors. British Journal of Pharmacology (2019) 176, S21–S141 THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G protein-coupled receptors Stephen PH Alexander1 , Arthur Christopoulos2 , Anthony P Davenport3 , Eamonn Kelly4, Alistair Mathie5 , John A Peters6 , Emma L Veale5 ,JaneFArmstrong7 , Elena Faccenda7 ,SimonDHarding7 ,AdamJPawson7 , Joanna L Sharman7 , Christopher Southan7 , Jamie A Davies7 and CGTP Collaborators 1School of Life Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK 2Monash Institute of Pharmaceutical Sciences and Department of Pharmacology, Monash University, Parkville, Victoria 3052, Australia 3Clinical Pharmacology Unit, University of Cambridge, Cambridge, CB2 0QQ, UK 4School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol, BS8 1TD, UK 5Medway School of Pharmacy, The Universities of Greenwich and Kent at Medway, Anson Building, Central Avenue, Chatham Maritime, Chatham, Kent, ME4 4TB, UK 6Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK 7Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh, EH8 9XD, UK Abstract The Concise Guide to PHARMACOLOGY 2019/20 is the fourth in this series of biennial publications. The Concise Guide provides concise overviews of the key properties of nearly 1800 human drug targets with an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. Although the Concise Guide represents approximately 400 pages, the material presented is substantially reduced compared to information and links presented on the website.
    [Show full text]
  • Pharmaceutical Appendix to the Harmonized Tariff Schedule
    Harmonized Tariff Schedule of the United States Basic Revision 3 (2021) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States Basic Revision 3 (2021) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,026,285 B2 Bezwada (45) Date of Patent: Sep
    US008O26285B2 (12) United States Patent (10) Patent No.: US 8,026,285 B2 BeZWada (45) Date of Patent: Sep. 27, 2011 (54) CONTROL RELEASE OF BIOLOGICALLY 6,955,827 B2 10/2005 Barabolak ACTIVE COMPOUNDS FROM 2002/0028229 A1 3/2002 Lezdey 2002fO169275 A1 11/2002 Matsuda MULT-ARMED OLGOMERS 2003/O158598 A1 8, 2003 Ashton et al. 2003/0216307 A1 11/2003 Kohn (75) Inventor: Rao S. Bezwada, Hillsborough, NJ (US) 2003/0232091 A1 12/2003 Shefer 2004/0096476 A1 5, 2004 Uhrich (73) Assignee: Bezwada Biomedical, LLC, 2004/01 17007 A1 6/2004 Whitbourne 2004/O185250 A1 9, 2004 John Hillsborough, NJ (US) 2005/0048121 A1 3, 2005 East 2005/OO74493 A1 4/2005 Mehta (*) Notice: Subject to any disclaimer, the term of this 2005/OO953OO A1 5/2005 Wynn patent is extended or adjusted under 35 2005, 0112171 A1 5/2005 Tang U.S.C. 154(b) by 423 days. 2005/O152958 A1 7/2005 Cordes 2005/0238689 A1 10/2005 Carpenter 2006, OO13851 A1 1/2006 Giroux (21) Appl. No.: 12/203,761 2006/0091034 A1 5, 2006 Scalzo 2006/0172983 A1 8, 2006 Bezwada (22) Filed: Sep. 3, 2008 2006,0188547 A1 8, 2006 Bezwada 2007,025 1831 A1 11/2007 Kaczur (65) Prior Publication Data FOREIGN PATENT DOCUMENTS US 2009/0076174 A1 Mar. 19, 2009 EP OO99.177 1, 1984 EP 146.0089 9, 2004 Related U.S. Application Data WO WO9638528 12/1996 WO WO 2004/008101 1, 2004 (60) Provisional application No. 60/969,787, filed on Sep. WO WO 2006/052790 5, 2006 4, 2007.
    [Show full text]
  • Prolongation of the Life Span of Cardiomyopathic Hamster by the Adrenergic 8 1-Selective Partial Agonist Denopamine
    Prolongation of the Life Span of Cardiomyopathic Hamster by the Adrenergic 8 1-Selective Partial Agonist Denopamine Hideo Kurosawa', Hiroshi Narita2,*, Minako Kaburaki2, Hideo Yabanal, Hisayoshi Doi2, Emiko Itogawa' and Masahito Okamoto2 'Lead Optimization Research Laboratory and 2Pharmaceutical Development Research Laboratory , Tanabe Seiyaku Co., Ltd., 2-2-50 Toda, Saitama 335, Japan Received May 24, 1996 Accepted September 11, 1996 ABSTRACT-Influence of cardiotonic agents on the prognosis of heart failure depends on the individual therapeutic agents, and favorable and unfavorable effects of these agents have been reported in clinical trials. We studied the effect of the cardiotonic agent denopamine on the life span of cardiomyopathic hamsters (BIO 14.6 strain) in the heart failure period. Non-treated hamsters started to die at 40 weeks of age, and their survival rate decreased to 23.8% at the age of 65 weeks. Hamsters treated with denopamine (400 ppm in diet) from 36 weeks of age did not die until the age of 52 weeks, except in cases of accidental death. The survival rate of this group at 65 weeks of age was about 40%. Survival rates of these 2 groups were sig- nificantly different (P<0.05) when animals with accidental death were excluded. To elucidate the mecha- nism of the effect of denopamine, we performed several experiments after dietary treatment with denopamine for 4 to 6 weeks from 37 weeks of age. Denopamine treatment lowered plasma levels of noradrenaline and dopamine (P <0.05), but affected neither the cardiac contractility nor the j3-adrenoceptor density. In sum- mary, denopamine significantly decreases the mortality of cardiomyopathic hamsters.
    [Show full text]
  • Molecular Properties of Drugs Interacting with SLC22 Transporters OAT1, OAT3, OCT1, and OCT2: a Machine-Learning Approach S
    Supplemental material to this article can be found at: http://jpet.aspetjournals.org/content/suppl/2016/08/03/jpet.116.232660.DC1 1521-0103/359/1/215–229$25.00 http://dx.doi.org/10.1124/jpet.116.232660 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS J Pharmacol Exp Ther 359:215–229, October 2016 Copyright ª 2016 by The American Society for Pharmacology and Experimental Therapeutics Molecular Properties of Drugs Interacting with SLC22 Transporters OAT1, OAT3, OCT1, and OCT2: A Machine-Learning Approach s Henry C. Liu, Anne Goldenberg, Yuchen Chen, Christina Lun, Wei Wu, Kevin T. Bush, Natasha Balac, Paul Rodriguez, Ruben Abagyan, and Sanjay K. Nigam Departments of Bioengineering (H.C.L.), Pediatrics (A.G., Y.C., C.L., K.T.B., S.K.N.), Medicine (W.W., S.K.N.), Cellular and Molecular Medicine (S.K.N.), and Pharmacology (R.A.), and the San Diego Supercomputer Center (N.B., P.R.), University of California San Diego, La Jolla, California Downloaded from Received February 2, 2016; accepted July 20, 2016 ABSTRACT Statistical analysis was performed on physicochemical descrip- ligands; this was confirmed by quantitative atomic property field tors of ∼250 drugs known to interact with one or more SLC22 analysis. Virtual screening with this pharmacophore, followed by “drug” transporters (i.e., SLC22A6 or OAT1, SLC22A8 or OAT3, transport assays, identified several cationic drugs that selectively jpet.aspetjournals.org SLC22A1 or OCT1, and SLC22A2 or OCT2), followed by applica- interact with OAT3 but not OAT1. Although the present analysis tion of machine-learning methods and wet laboratory testing of may be somewhat limited by the need to rely largely on inhibition novel predictions.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]